---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-037600"
form_type: "8-K"
ticker: "HURA"
cik: "0001498382"
company_name: "TuHURA Biosciences, Inc./NV"
filed_at: "2025-03-12T23:59:59+00:00"
generated_at: "2026-05-24T22:18:04.087405+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# TuHURA appoints Dr. Craig Tendler (ex-J&J oncology VP) to Board, effective March 10, 2025

## Summary
- Dr. Tendler oversaw 30 major oncology drug approvals at J&J, including DARZALEX, ZYTIGA, and BALVERSA.
- Received option to purchase 151,883 shares of HURA common stock at closing price on grant date.
- TuHURA plans to begin Phase 3 trial of IFx-2.0 in Q2 2025; Tendler's experience expected to aid regulatory strategy.
- Board expanded from five to six members with this appointment.

## SEC filing metadata
- accession: 0000950170-25-037600
- form_type: 8-K
- ticker: HURA
- cik: 0001498382
- company_name: TuHURA Biosciences, Inc./NV
- filed_at: 2025-03-12T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1498382/000095017025037600/0000950170-25-037600-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1498382/000095017025037600/hura-20250307.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-037600
- JSON: https://secwatch.observer/filing/0000950170-25-037600.json
- Plain text: https://secwatch.observer/filing/0000950170-25-037600.txt

## Key facts
- Executive change
  Craig Tendler was appointed as Director at TuHURA Biosciences, Inc./NV.
  - Action: appointed
  - Role: Director
  source text: On March 7, 2025, the Board of Directors (the “Board”) of TuHURA Biosciences, Inc. (the “Company”) increased the size of the Board from five members to six members and appointed Dr. Craig Tendler to the Board, effective as of March 10, 2025, to serve as a director until the Company’s 2025 Annual Meeting of Stockholders and until his successor has been duly elected and qualified or until his earlier death, resignation or removal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1498382/000095017025037600/0000950170-25-037600-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.